Antiandrogens
Aspirin
Bamlaniv../e..
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Melatonin (meta)
Aspirin (meta) Metformin (meta)
Bamlaniv../e.. (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Lactoferrin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Case 93% Improvement Relative Risk c19hcq.com/simovapep.html Favors HCQ Favors control
12 November 2020 - Post Exposure Prophylaxis study (treated after exposure to the virus)
Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health care workers
Simova et al., New Microbes and New Infections, doi:10.1016/j.nmni.2020.100813 (Peer Reviewed)
Source   PDF   Share   Tweet
100% reduction in cases with HCQ+zinc post-exposure prophylaxis. Brief report for healthcare workers in Bulgaria.
0 cases with treatment vs. 3 for control.
156 treatment patients and 48 control patients.
No serious adverse events. This paper reports on both PEP and early treatment, we have separated the two studies.
risk of case, 92.7% lower, RR 0.07, p = 0.01, treatment 0 of 156 (0.0%), control 3 of 48 (6.2%), NNT 16, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes.
Simova et al., 11/12/2020, retrospective, Bulgaria, Europe, peer-reviewed, 5 authors.
All Studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Submit